Alkermes, Inc.
Alkermes, Inc., a prominent biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for central nervous system (CNS) disorders and addiction. Founded in 1987, Alkermes has established itself as a leader in the industry, with significant operational presence across North America and Europe. The company is renowned for its unique drug delivery technologies and a robust portfolio of products, including treatments for schizophrenia, depression, and opioid dependence. Alkermes' commitment to addressing complex medical needs has positioned it favourably in the market, with notable achievements in advancing patient care through its proprietary formulations. With a strong emphasis on research and development, Alkermes continues to drive innovation in the biopharmaceutical landscape.
DitchCarbon Score
How does Alkermes, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alkermes, Inc.'s score of 23 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alkermes, Inc.'s reported carbon emissions
In 2017, Alkermes, Inc. reported total carbon emissions of approximately 337,524,000 kg CO2e for Scope 1 and 110,525,000 kg CO2e for Scope 2. The company also disclosed Scope 3 emissions, which included 177,000 kg CO2e from capital goods, 60,000 kg CO2e from purchased goods and services, 20,000 kg CO2e from waste generated in operations, and 28,000 kg CO2e from fuel and energy-related activities. Over the years, Alkermes has shown a trend of decreasing emissions. For instance, in 2016, their Scope 1 emissions were about 345,064,000 kg CO2e, and Scope 2 emissions were approximately 104,210,000 kg CO2e. This indicates a commitment to reducing their carbon footprint, although specific reduction targets or initiatives have not been disclosed. Alkermes has reported emissions data for all three scopes, demonstrating transparency in their climate impact. However, there are no documented reduction targets or climate pledges available, suggesting that while they are tracking emissions, they may not have formalised commitments to specific reduction goals at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | |
|---|---|---|---|
| Scope 1 | 412,205,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 112,198,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 290,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alkermes, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
